SCHEMBL22816474

SCHEMBL22816474

CCOC(=O)c1nnn(Cc2ccc(OC)cc2)c1Nc1ccc(Cl)c(Cl)c1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
HSD17B10 Q99714 3/20 0.46
HPGD P15428 2/20 0.46
POLB P06746 3/20 0.45
MAPT P10636 2/20 0.45
RXFP1 Q9HBX9 1/20 0.45
ALOX15 P16050 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
CYP19A1 P11511 4/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
ALDH1A1 P00352 4/20 0.43
KDM4E B2RXH2 3/20 0.43
RAF1 P04049 1/20 0.43
DHODH Q02127 1/20 0.43
GUSB P08236 1/20 0.43
RECQL P46063 1/20 0.42
UCHL1 P09936 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22816685 0.93 CYP19A1 (0.46) MEN1KMT2AHSD17B10HPGDPOLB
SCHEMBL21296878 0.91 MEN1 (0.51) MEN1KMT2AHSD17B10HPGDPOLB
SCHEMBL22816547 0.89 CYP19A1 (0.47) MEN1KMT2AHSD17B10HPGDPOLB
SCHEMBL22815946 0.89 CYP19A1 (0.50) MEN1KMT2AHSD17B10HPGDPOLB
SCHEMBL22816734 0.88 CYP19A1 (0.48) MEN1KMT2AHSD17B10HPGDPOLB
SCHEMBL22816473 0.88 MEN1 (0.48) MEN1KMT2AHSD17B10HPGDPOLB
SCHEMBL22816573 0.88 MEN1 (0.49) MEN1KMT2AHSD17B10HPGDPOLB
SCHEMBL22815669 0.86 CYP19A1 (0.56) MEN1KMT2AHSD17B10HPGDPOLB
SCHEMBL22816819 0.86 CYP19A1 (0.48) MEN1KMT2AHSD17B10HPGDPOLB
SCHEMBL22816857 0.86 CYP19A1 (0.48) MEN1KMT2AHSD17B10HPGDPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11384055-B2 Glycolate oxidase inhibitors for the treatment of disease BIOMARIN PHARMACEUTICAL INC. (US) 2022-07-12 US disclosed
US-20210171474-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2021-06-10 US disclosed
WO-2020257487-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2020-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11384055-B2 Glycolate oxidase inhibitors for the treatment of disease XDH, PNPO, AGXT MEN1 2988/4885KMT2A 4011/4885HSD17B10 296/4885
US-20210171474-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE XDH, PNPO, AGXT MEN1 2988/4885KMT2A 4011/4885HSD17B10 296/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.